Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corgenix enters US bio-terrorism defence programme:

This article was originally published in Clinica

Executive Summary

Immunoassay firm Corgenix Medical has formed a bio-terrorism defence programme to develop a rapid detection system for viral haemorrhagic fevers. The US Centers for Disease Control and Prevention (CDC) classifies viral haemorrhagic fever as a high priority "category A" biological disease due to its risk as a potential agent of bio-terrorism. Denver, Colorado-based Corgenix said it had requested additional funding from the National Institutes of Health (NIH) to help develop the project.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts